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To the Editor: Soft-tissue inju-
ries sustained during wars are sub-
ject to environmental contamination 
and, thus, to a high risk for infection. 
Efforts to describe the epidemiol-
ogy of war-associated infections are 
complicated by difficult access to 
patients, limited availability of mi-
crobiology support, and widespread 
empirical antimicrobial drug use. 
Nevertheless, identifying the relevant 
pathogens is critical because war-as-
sociated injuries commonly become 
infected and antimicrobial drug–re-
sistant bacteria are well-described in 
these injuries, including those in the 
Middle East (1–3).
The Médecins Sans Frontières 
(MSF) surgical project in Amman, 
Jordan, was initially developed for 
war-injured Iraqis needing surgical re-
construction or management of chron-
ic osteomyelitis. Infection manage-
ment is based on organism-directed 
antimicrobial agents and wide surgi-
cal resection of involved tissue. The 
proximity of this project to the Syr-
ian conflict provided an opportunity 
to describe microbiologic features of 
infections caused by war-associated 
injuries in Syrians, who may be at in-
creased risk for infection-associated 
complications because of exclusion 
from care in official health systems. 
We describe a cross-sectional series of 
61 Syrian orthopedic patients who had 
suspected infections, as determined on 
the basis of surgical samples obtained 
intraoperatively.
Syrian patients admitted to the 
MSF clinic underwent initial surgi-
cal exploration of wounds; if infec-
tion was suspected, >3 intraopera-
tive samples (bone, fibrous tissue, 
fluid) were obtained for culture and 
transported (at 4°–8°C) within 2 h 
to the laboratory at Ibn al-Haytham 
Hospital in Amman. Patients who 
were treated with antimicrobial drugs 
within 2 weeks before admission 
were excluded from analysis.
We retrospectively reviewed data 
for patients admitted during August 1, 
2011–March 31, 2013. Data were col-
lected from databases and individual 
charts in Amman and analyzed by us-
ing Stata 12 (http://www.stata.com/
stata12/). This study was deemed ex-
empt from additional ethical approval 
by the MSF review board because it 
involved routinely collected data.
We defined a multidrug-resistant 
(MDR) isolate as 1) extended-spec-
trum β-lactamase–expressing Entero-
bacteriaceae; 2) Pseudomonas aeru-
ginosa and Acinetobacter baumannii 
isolates resistant to at least 1 agent in 3 
antimicrobial categories typically used 
for treatment; or 3) methicillin-resis-
tant Staphylococcus aureus (MRSA). 
Pathogen identification was conducted 
by using conventional methods and 
the API system (bio-Mérieux, Dur-
ham, NC, USA). Antimicrobial drug 
susceptibility testing was conducted 
by using the MicroScan Walk-Away 
System (Dade Behring, West Sacra-
mento, CA, USA).
During the study period, 870 pa-
tient consultations were conducted, 
of which 345 (40%) were for patients 
from Syria. At the initial operating 
room evaluation, infection was sus-
pected in 61 (18%) Syrians. These 
patients had a median age of 26 years 
(interquartile range 22–34); 98% were 
male. The median time from injury to 
admission was 5 months (interquartile 
range 1.2–8.1), but for 27 (44%) pa-
tients, the time from injury to admis-
sion was >6 months. The 2 most com-
mon injuries were gunshot wounds 
(32 patients [52%]) and wounds from 
explosions (20 patients [33%]). The 
dominant injury was located in an up-
per extremity in 14 (23%) patients and 
a lower extremity in 47 (77%) patients.




For the 61 patients, a total of 67 
bacterial isolates were identified from 
cultures of surgical specimens. Overall, 
45 (74%) patients had at least 1 posi-
tive culture, and 6 (13%) patients had 
polymicrobial results. Gram-negative 
organisms represented 24 (56%) of 43 
isolates; 10 (23%) were P. aeruginosa, 
8 (19%) were E. coli, and 6 (14%) were 
A. baumannii. Gram-positive bacteria, 
including MRSA, represented 19 (44%) 
of 43 isolates (Table). Overall, 31 (69%) 
of 45 patients with confirmed infection 
were positive for MDR organisms. 
Within this group, MRSA represented 
8 (42%) of 19 staphylococcal isolates.
Patients who had experienced de-
layed definitive management were fre-
quently positive for MDR organisms, 
especially gram-negative pathogens 
and MRSA. For a humanitarian surgi-
cal project, infection with MDR organ-
isms leads to formidable diagnostic, 
treatment, and control challenges. For 
example, treatment of MDR infections 
requires ongoing access to high-quali-
ty clinical microbiology support; late-
generation antimicrobial drugs, which 
are typically given parenterally for up 
to 6 weeks; trained personnel; and suf-
ficient hospital space to isolate patients 
with resistant strains. Our findings 
support the previously reported link-
age between war-associated injuries 
and infection with antimicrobial drug–
resistant organisms (1–4) and the im-
plications for patient management.
The source of antimicrobial drug–
resistant organisms in war-associated 
injuries remains uncertain; possibili-
ties include nosocomial transmission 
(5), particularly through prior contact 
with severely compromised health 
systems (6). Another possibility is fe-
cal colonization with extended-spec-
trum β-lactamase–producing gram-
negative bacteria. (7,8). Another likely 
contributor in Syria is the wide avail-
ability of antimicrobial drugs without 
a prescription (9).
This study has limitations. Al-
though measures were taken to ensure 
that positive cultures represented clini-
cal infection rather than colonization, 
we cannot exclude colonization as a 
possible source of some recovered or-
ganisms. In neglected war-associated 
injuries, multiple pathogens are poten-
tially present, but every strain is not 
necessarily clinically relevant (10). 
Furthermore, complete patient histories 
are difficult to obtain in crisis settings, 
limiting our ability to describe all prior 
interventions. Study strengths included 
partnership with a high-quality culture 
laboratory, which is uncommon in pro-
grams treating war injuries; systemic 
sampling of patients with suspected 
infection; and use of intraoperative 
samples for culture. Further research 
needed in this neglected area includes 
prospective studies to determine the 
effect of MDR isolates on patient out-
comes and randomized clinical trials of 
antimicrobial drug strategies to inform 
treatment protocols.
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aureus,	n = 19 
Pseudomonas 
aeruginosa,	n =	10 Escherichia coli,	n =	8 
Acinetobacter 
baumannii,	n =	6 
Amikacin  1/	11	(9)	 1/7	(14) 6/6	(100) 
Ampicillin   5/5	(100)  
Amoxicillin/clavulanic	acid   6/6	(100)  
Cefotaxime   6/8	(75)  
Ceftriaxone   5/8	(62)  
Ceftazidime  3/9	(33) 5/8	(62) 4/4	(100) 
Cefepime   5/8	(62) 5/5	(100) 
Cefixime   5/8	(62) 5/5	(100) 
Ciprofloxacin 7/17	(41) 5/8	(62) 2/7	(28) 5/5	(100) 
Colistin  NA NA 0/5 
Trimethoprim/sulfamethoxazole 3/14	(21)  3/5	(60)  
Gentamicin 10/18	(55) 4/9	(44) 4/8	(50) 6/6	(100) 
Piperacillin/tazobactam  2/9	(22) 3/7	(42) NA 
Imipenem  0/9 1/7	(14) 4/5	(80) 
Penicillin 9/10	(90)    
Oxacillin 7/17	(41)    
Clindamycin 9/17	(52)    
Rifampin 6/15	(40)    
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Multidrug-Resistant 
IncA/C Plasmid  
in Vibrio cholerae 
from Haiti
To the Editor: The agents of 
epidemic cholera are Vibrio cholerae 
toxigenic serogroups O1 and O139. 
Cholera symptoms include watery di-
arrhea and severe dehydration, which 
can rapidly result in death unless rehy-
dration therapy is prompt (1). Antimi-
crobial agents may reduce the severity 
and duration of disease (1); commonly 
used are tetracyclines, fluoroquino-
lones, macrolides, and trimethoprim/
sulfamethoxazole (1). However, V. 
cholerae resistance to antimicrobial 
drugs is increasing because of the ac-
cumulation of genetic mutations and 
the acquisition of resistance genes, 
which are usually transferred on mo-
bile genetic elements such as integrat-
ing conjugative elements (ICEs) (1).
As of March 12, 2014, the on-
going cholera outbreak that began 
in Haiti in October 2010 had caused 
700,796 cases and 8,548 deaths (2). To 
characterize infections, the National 
Public Health Laboratory in Haiti and 
the US Centers for Disease Control 
and Prevention (CDC) collaborated 
to perform standard microbiological 
and antimicrobial-drug susceptibility 
testing on isolates from case-patients. 
Since October 2010, the National 
Public Health Laboratory has identi-
fied 465 isolates, which were then for-
warded to CDC for determination of 
MICs for 15 antimicrobial agents by 
broth microdilution (Sensititer; Trek 
Diagnostics Systems, Cleveland, OH, 
USA) according to manufacturer’s 
recommendations (Table). Resistance 
was defined by the Clinical and Labo-
ratory Standards Institute interpretive 
standards, when available (3). The 
typical outbreak strain (2010EL-1786) 
displayed resistance to streptomycin, 
sulfisoxazole, trimethoprim/sulfa-
methoxazole, and nalidixic acid, and 
decreased susceptibility to ciprofloxa-
cin and chloramphenicol (4). Resis-
tance was caused by mutations in the 
QRDR regions of the gyrA and parC 
genes and presence of ICEVchHai1 
containing the dfrA1, floR, strAB, and 
sul2 resistance genes (4).
In April of 2012, the 2 agencies 
began sentinel laboratory-based sur-
veillance for acute diarrheal disease 
at 4 hospitals in Haiti (5). As part of 
this surveillance, fecal specimens were 
sent to the National Public Health Lab-
oratory for organism isolation, identifi-
cation, antimicrobial-drug testing, and 
subsequently to CDC for expanded an-
timicrobial-drug testing and molecular 
characterization. One isolate, 2012EL-
2176, showed the typical resistance 
phenotype of the outbreak strain but 
additional resistance to ampicillin, 
amoxicillin/clavulanic acid, cefoxitin, 
ceftriaxone, ceftiofur; the tetracycline 
MIC was intermediate (Table).
Analysis of this isolate by sero-
type, pulsed-field gel electrophoresis, 
multilocus variable number–tandem 
repeat analysis, and whole-genome 
sequencing confirmed that the isolate 
was similar to outbreak isolates (data 
not shown) (6). PCR and whole-ge-
nome sequencing analysis by use of 
ResFinder (http://www.genomicepi-
demiology.org/) identified the original 
outbreak resistance determinants and 
additional determinants (aac(3)-IIa, 
blaCMY-2, blaCTX-M-2, blaTEM-1, dfrA15, 
